指南与共识心律失常心力衰竭与心肌病

2017 AHA/ACC/HRS 室性心律失常与心脏性猝死预防指南的系统综述

Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
指南 / 共识 · J Am Coll Cardiol · 2017-10-30

本系统综述针对2017年AHA/ACC/HRS室性心律失常指南的两个问题进行证据评估:无症状Brugada综合征患者电生理检查诱发室性心律失常的预后价值,以及ICD在老年和合并症患者中的获益。分析显示,诱发心律失常未显著增加主要心律失常事件风险(OR 2.3,95%CI 0.63-8.66,p=0.2);ICD植入与老年及合并症患者生存改善相关(总体HR 0.75,95%CI 0.67-0.83,p<0.001)。

要点

  • 无症状Brugada综合征患者电生理诱发室性心律失常未显著预测主要心律失常事件。
  • ICD植入与老年(>75岁)患者生存改善相关(HR 0.75,95%CI 0.67-0.83)。
  • 合并症患者ICD植入与全因死亡率降低相关(HR 0.72,95%CI 0.65-0.79)。

核心结论

  • 无症状Brugada综合征患者电生理检查诱发室性心律失常未显著增加主要心律失常事件风险。
  • ICD植入与老年及合并症患者生存改善相关,支持在符合适应证者中考虑ICD。

研究设计与样本

  • 系统综述采用传统统计方法分析已发表研究。
  • Brugada综合征分析纳入6项研究共1138例无症状患者。

主要发现

  • 无症状Brugada综合征患者中390例(34.3%)电生理检查可诱发室性心律失常。
  • 主要分析(5项研究)显示诱发组主要心律失常事件OR 2.3(95%CI 0.63-8.66;p=0.2)。
  • ICD植入与老年患者生存改善相关(HR 0.75;95%CI 0.67-0.83;p<0.001)。
  • 合并症患者ICD植入与全因死亡率降低相关(HR 0.72;95%CI 0.65-0.79;p<0.0001)。
  • 肾功能不全亚组ICD植入与全因死亡率降低相关(HR 0.71;95%CI 0.60-0.85;p<0.001)。

临床怎么用

  • 对无症状Brugada综合征患者,不应仅依据电生理诱发结果决定治疗。
  • 老年(>75岁)患者若符合ICD适应证,植入ICD可能改善生存。
  • 合并症患者若符合ICD适应证,植入ICD可能降低全因死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although large randomized clinical trials have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves survival in patients with cardiomyopathy and heart failure symptoms, patients who receive ICDs in practice are often older and have more comorbidities than patients who were enrolled in the clinical trials. In addition, there is a debate among clinicians on the usefulness of electrophysiological study for risk stratification of asymptomatic patients with Brugada syndrome. AIM: Our analysis has 2 objectives. First, to evaluate whether ventricular arrhythmias (VAs) induced with programmed electrostimulation in asymptomatic patients with Brugada syndrome identify a higher risk group that may require additional testing or therapies. Second, to evaluate whether implantation of an ICD is associated with a clinical benefit in older patients and patients with comorbidities who would otherwise benefit on the basis of left ventricular ejection fraction and heart failure symptoms. METHODS: Traditional statistical approaches were used to address 1) whether programmed ventricular stimulation identifies a higher-risk group in asymptomatic patients with Brugada syndrome and 2) whether ICD implantation for primary prevention is associated with improved outcomes in older patients (>75 years of age) and patients with significant comorbidities who would otherwise meet criteria for ICD implantation on the basis of symptoms or left ventricular function. RESULTS: Evidence from 6 studies of 1138 asymptomatic patients were identified. Brugada syndrome with inducible VA on electrophysiological study was identified in 390 (34.3%) patients. To minimize patient overlap, the primary analysis used 5 of the 6 studies and found an odds ratio of 2.3 (95% CI: 0.63-8.66; p=0.2) for major arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asymptomatic patients with Brugada syndrome and inducible VA on electrophysiological study versus those without inducible VA. Ten studies were reviewed that evaluated ICD use in older patients and 4 studies that evaluated unique patient populations were identified. In our analysis, ICD implantation was associated with improved survival (overall hazard ratio: 0.75; 95% confidence interval: 0.67-0.83; p<0.001). Ten studies were identified that evaluated ICD use in patients with various comorbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, heart disease, and others. A random effects model demonstrated that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.72; 95% confidence interval: 0.65-0.79; p<0.0001), and a second "minimal overlap" analysis also found that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.61-0.82; p<0.0001). In 5 studies that included data on renal dysfunction, ICD implantation was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.60-0.85; p<0.001).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017. PMID: 29097297. doi:10.1016/j.jacc.2017.10.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。